tert-butyl N-[(1R)-1-(tert-butoxymethyl)-2-hydroxyethyl]carbamate | 1016606-77-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[(1R)-1-(tert-butoxymethyl)-2-hydroxyethyl]carbamate
• 英文别名: tert-butyl N-[(2R)-1-hydroxy-3-[(2-methylpropan-2-yl)oxy]propan-2-yl]carbamate
• CAS: 1016606-77-1
• 化学式: C₁₂H₂₅NO₄
• 分子量: 247.335
• InChiKey: RCOODHLCPDVVPW-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(1R)-1-(tert-butoxymethyl)-2-hydroxyethyl]carbamate 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 、 氨 、 戴斯-马丁氧化剂 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 17.75h， 生成 tert-butyl ((5S,10R)-5-amino-10-(tert-butoxymethyl)-14,14-dimethyl-3,6,12-trioxo-1,1,1-triphenyl-13-oxa-2,7,8,11-tetraazapentadecan-8-yl)formate
  参考文献：
  名称：

  PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS

  摘要：

  本发明涉及作为治疗剂的新型肽类似物化合物，能够抑制程序性细胞死亡1（PD1）信号通路。该发明还涉及这些治疗剂的衍生物。该发明还包括利用所述治疗剂和衍生物治疗通过免疫增强来抑制由于PD-1、PD-L1或PD-L2引起的免疫抑制信号的障碍，并使用它们进行治疗的疗法。

  公开号：

  US20130237580A1
• 作为产物：
  描述：

  methyl N-(tert-butoxycarbonyl)-O-(tert-butyl)-L-serinate 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以100%的产率得到tert-butyl N-[(1R)-1-(tert-butoxymethyl)-2-hydroxyethyl]carbamate
  参考文献：
  名称：

  PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS

  摘要：

  本发明涉及作为治疗剂的新型肽类似物化合物，能够抑制程序性细胞死亡1（PD1）信号通路。该发明还涉及这些治疗剂的衍生物。该发明还包括利用所述治疗剂和衍生物治疗通过免疫增强来抑制由于PD-1、PD-L1或PD-L2引起的免疫抑制信号的障碍，并使用它们进行治疗的疗法。

  公开号：

  US20130237580A1

文献信息

• Synthesis of threo-β-aminoalcohols from aminoaldehydes via chelation-controlled additions. Total synthesis of l-threo sphingosine and safingol
  作者：Michael E. Jung、Sung Wook Yi

  DOI：10.1016/j.tetlet.2012.05.153

  日期：2012.8

  threo-β-amino alcohol derivatives through chelation with the carbamoyl moiety. The carbamate group is a stronger chelating group than other potentially good chelators, for example ethers, esters, thioethers, and gives good diastereoselectivity with cuprates. Thus addition of lithium divinylcuprate to the aldehyde generated from the serine derivative 25 in the presence of extra copper for chelation

  由功能化氨基酸制备的N-氨基甲酰基氨基醛螯合控制的有机铜酸酯的添加主要通过与氨基甲酰基部分的螯合生成苏-β-氨基醇衍生物。氨基甲酸酯基团是比其他潜在的良好螯合剂（例如醚，酯，硫醚）更强的螯合基团，并且对铜酸盐具有良好的非对映选择性。因此，在额外的铜的存在下，将二乙烯基铜酸锂添加到由丝氨酸衍生物25产生的醛中进行螯合，以83％的收率得到苏式化合物26。保护基团的交叉复分解和裂解提供了l-苏式鞘氨醇21。另外，通过这种方法，由市售的O-苄基N -BOC丝氨酸28以六个步骤制备了溶血鞘脂蛋白激酶C抑制剂safingol，22，其总产率为56％。
• Therapeutic Compounds for Immunomodulation
  申请人：Sasikumar Pottayil G. N.

  公开号：US20140199334A1

  公开（公告）日：2014-07-17

  The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

  本发明提供了能够抑制程序性细胞死亡1（PD1）信号通路的免疫抑制化合物。本发明还提供了基于肽的组合物，通过抑制由PD-1，PD-L1或PD-L2诱导的免疫抑制信号而引起免疫增强，用于治疗癌症或感染的治疗方法，包括作为活性成分的免疫增强底物。此外，本发明提供了包含免疫抑制肽化合物或修饰肽基团的药物组合物，用于预防和/或治疗癌症，癌症转移，免疫缺陷，传染病或类似疾病的预防性和/或治疗性剂，并将PD-1或PD-L1应用为测试或诊断剂或用于此类疾病的研究剂。
• IMMUNOSUPPRESSION MODULATING COMPOUNDS
  申请人：Sasikumar Pottayil G. N.

  公开号：US20110318373A1

  公开（公告）日：2011-12-29

  The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
• Immunosuppression Modulating Compounds
  申请人：Sasikumar Pottayil Govindan Nair

  公开号：US20150087581A1

  公开（公告）日：2015-03-26

  The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
• US8907053B2
  申请人：——

  公开号：US8907053B2

  公开（公告）日：2014-12-09